Your browser doesn't support javascript.
loading
Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
Fortner, Renée T; Poole, Elizabeth M; Wentzensen, Nicolas A; Trabert, Britton; White, Emily; Arslan, Alan A; Patel, Alpa V; Setiawan, V Wendy; Visvanathan, Kala; Weiderpass, Elisabete; Adami, Hans-Olov; Black, Amanda; Bernstein, Leslie; Brinton, Louise A; Buring, Julie; Clendenen, Tess V; Fournier, Agnès; Fraser, Gary; Gapstur, Susan M; Gaudet, Mia M; Giles, Graham G; Gram, Inger T; Hartge, Patricia; Hoffman-Bolton, Judith; Idahl, Annika; Kaaks, Rudolf; Kirsh, Victoria A; Knutsen, Synnove; Koh, Woon-Puay; Lacey, James V; Lee, I-Min; Lundin, Eva; Merritt, Melissa A; Milne, Roger L; Onland-Moret, N Charlotte; Peters, Ulrike; Poynter, Jenny N; Rinaldi, Sabina; Robien, Kim; Rohan, Thomas; Sánchez, Maria-José; Schairer, Catherine; Schouten, Leo J; Tjonneland, Anne; Townsend, Mary K; Travis, Ruth C; Trichopoulou, Antonia; van den Brandt, Piet A; Vineis, Paolo; Wilkens, Lynne.
Afiliação
  • Fortner RT; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Poole EM; Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Wentzensen NA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
  • Trabert B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
  • White E; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Arslan AA; New York University School of Medicine, New York, NY.
  • Patel AV; Epidemiology Research Program, American Cancer Society, Atlanta, GA.
  • Setiawan VW; University of Southern California, Los Angeles, CA.
  • Visvanathan K; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Weiderpass E; Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
  • Adami HO; Department of Research, Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
  • Black A; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Bernstein L; Genetic Epidemiology Group, Folkhälsan Research Center, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Brinton LA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Buring J; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
  • Clendenen TV; City of Hope, Duarte, CA.
  • Fournier A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
  • Fraser G; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Gapstur SM; Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Gaudet MM; New York University School of Medicine, New York, NY.
  • Giles GG; CESP "Health across Generations," INSERM, Univ Paris-Sud, UVSQ, Univ Paris-Saclay, Villejuif, France.
  • Gram IT; Gustave Roussy, Villejuif, France.
  • Hartge P; Loma Linda University, Loma Linda, CA.
  • Hoffman-Bolton J; Epidemiology Research Program, American Cancer Society, Atlanta, GA.
  • Idahl A; Epidemiology Research Program, American Cancer Society, Atlanta, GA.
  • Kaaks R; Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
  • Kirsh VA; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
  • Knutsen S; Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
  • Koh WP; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Washington, D.C.
  • Lacey JV; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
  • Lee IM; Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
  • Lundin E; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Merritt MA; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
  • Milne RL; Loma Linda University, Loma Linda, CA.
  • Onland-Moret NC; Health Services and Systems Research, Duke-NUS Medical School Singapore, Singapore.
  • Peters U; City of Hope, Duarte, CA.
  • Poynter JN; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
  • Rinaldi S; Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
  • Robien K; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.
  • Rohan T; Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
  • Sánchez MJ; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG, United Kingdom.
  • Schairer C; Cancer Epidemiology & Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
  • Schouten LJ; Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
  • Tjonneland A; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Townsend MK; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Travis RC; Department of Pediatrics, University of Minnesota, Minneapolis, MN.
  • Trichopoulou A; International Agency for Research on Cancer, Lyon, France.
  • van den Brandt PA; Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, George Washington University, Washington, D.C.
  • Vineis P; Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
  • Wilkens L; Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Int J Cancer ; 145(1): 58-69, 2019 07 01.
Article em En | MEDLINE | ID: mdl-30561796
ABSTRACT
Ovarian cancer risk factors differ by histotype; however, within subtype, there is substantial variability in outcomes. We hypothesized that risk factor profiles may influence tumor aggressiveness, defined by time between diagnosis and death, independent of histology. Among 1.3 million women from 21 prospective cohorts, 4,584 invasive epithelial ovarian cancers were identified and classified as highly aggressive (death in <1 year, n = 864), very aggressive (death in 1 to < 3 years, n = 1,390), moderately aggressive (death in 3 to < 5 years, n = 639), and less aggressive (lived 5+ years, n = 1,691). Using competing risks Cox proportional hazards regression, we assessed heterogeneity of associations by tumor aggressiveness for all cases and among serous and endometrioid/clear cell tumors. Associations between parity (phet = 0.01), family history of ovarian cancer (phet = 0.02), body mass index (BMI; phet ≤ 0.04) and smoking (phet < 0.01) and ovarian cancer risk differed by aggressiveness. A first/single pregnancy, relative to nulliparity, was inversely associated with highly aggressive disease (HR 0.72; 95% CI [0.58-0.88]), no association was observed for subsequent pregnancies (per pregnancy, 0.97 [0.92-1.02]). In contrast, first and subsequent pregnancies were similarly associated with less aggressive disease (0.87 for both). Family history of ovarian cancer was only associated with risk of less aggressive disease (1.94 [1.47-2.55]). High BMI (≥35 vs. 20 to < 25 kg/m2 , 1.93 [1.46-2.56] and current smoking (vs. never, 1.30 [1.07-1.57]) were associated with increased risk of highly aggressive disease. Results were similar within histotypes. Ovarian cancer risk factors may be directly associated with subtypes defined by tumor aggressiveness, rather than through differential effects on histology. Studies to assess biological pathways are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Epitelial do Ovário Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged / Pregnancy Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Carcinoma Epitelial do Ovário Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Middle aged / Pregnancy Idioma: En Ano de publicação: 2019 Tipo de documento: Article